Newsletter Login

Username:

Password:


Need help logging in?

New Subscriber?
Start Here!

Stock Spotlight

LabCorp passes growth test

Recent Price
$137
Dividend
$0.00
Yield
0.0%
P/E Ratio
17
Shares (millions)
104
Long-Term Debt as % of Capital
54%
52-Week Price Range
$137.48 - $97.79



Laboratory Corp. of America ($137; LH), one of just two national laboratory operators, benefits from pricing power and the current environment of rising medical utilization. Although hospitals still conduct about half of clinical lab work in the U.S., they increasingly outsource testing to companies like LabCorp. The U.S. accounts for 82% of revenue and Canada 5%, limiting LabCorp's exposure to the uncertainty gripping Europe after the U.K. voted to leave the European Union.

The stock has risen 5% this year, well above the S&P 500's 1% gain, yet still looks attractively priced, earning a Quadrix Value score of 67. LabCorp, scoring above 75 for both sector-specific ranks, is a Buy and a Long-Term Buy.

Business breakdown

Over the years, LabCorp has aggressively snapped up smaller labs to push its share of the U.S. lab market to 11%. It took a new direction in February 2015, paying $6.15 billion to acquire Covance, a contract research organization (CRO) that tests drugs for pharmaceutical companies. LabCorp's traditional diagnostics unit now represents about 73% of revenue, with the remaining 27% coming from drug-development services.

The deal came at a time when demand for new drug development was strong and LabCorp's core diagnostics business faced pressure from lower reimbursement rates. Covance reduced LabCorp's exposure to managed-care providers, Medicaid, and Medicare. LabCorp can also tap its database of 75 million patients to recruit subjects for clinical trials.

The merger is already paying off. March-quarter sales jumped 30%, from a combination of LabCorp's core testing business (6%) and Covance (24%). Testing volumes rose 4%, with slightly higher pricing. Both cash from operations and free cash flow more than doubled in the 12 months ended March and currently stand at all-time highs. LabCorp plans to use excess cash to pay down the $6.39 billion in debt on its balance sheet. It also expects to resume share repurchases in the second half of the year.

Earlier this year, rumors swirled that LabCorp held preliminary talks to purchase INC Research Holdings ($43; INCR), a CRO with a stock-market value of $2 billion. Management says it currently has no intention of making another big acquisition, though the pipeline for smaller deals is likely robust, given competitive challenges facing smaller labs.

Conclusion

Citing improvement at its core lab business and strength from Covance, LabCorp raised its 2016 guidance in April. Management now expects earnings per share to increase 8% to 13% on revenue growth of 8.5% to 10.5%.

At 16 times trailing earnings, the stock trades in line with its five-year average but well below the median P/E of 21 for S&P 1500 health-services stocks. If LabCorp earns $8.55 per share this year, the bottom of its projected profit range, and its trailing P/E ratio rises to 18, the shares will advance to $154 by early 2017.

An annual report for Laboratory Corp. of America Holdings is available at 358 S. Main St., Burlington, NC 27215; (336) 229-1127; www.labcorp.com.


 

Laboratory Corp. of America

 
Quarter
Per-Share Earnings
Sales Change
Quarterly Price Range
P/E Ratio Range
Mar '16
$2.02
vs.
$1.76
32%
$123.99
-
$97.79
16 - 12
Dec '15
1.98
vs.
1.65
52%
126.24
-
107.30
17 - 14
Sep '15
2.07
vs.
1.80
49%
128.84
-
105.77
18 - 14
Jun '15
2.09
vs.
1.84
50%
129.33
-
116.00
18 - 16

 
Year (Dec.)
Sales (Bil.)
Per-Share Earnings*
Per-Share Dividend
52-Week Price Range
P/E Ratio Range
2015
$8.68
$7.91
$0.00
$131.19
-
$105.77
17 - 13
2014
6.01
6.80
0.00
109.84
-
87.25
16 - 13
2013
5.81
6.95
0.00
108.00
-
85.80
16 - 12
2012
5.67
6.82
0.00
95.30
-
81.56
14 - 12

 
Quadrix Scores†
Overall
Momentum
Value
Quality
Financial Strength
Earnings Estimates
Performance
94
95
67
70
49
96
69

* Earnings exclude special items.
NM Not Meaningful.
† Quadrix® scores are percentile ranks, with 100 the best.
e Dividend and yield estimated.

More Investment Newsletters and Services

Drip Investor

DRIP Investor — how you can buy dividend-paying stocks without a broker.

Visit us at DRIP Investor, your source for dividend reinvestment plans.

Lazy Investor

The Lazy Investor — free weekly e-letter that delivers market updates and stock market information via email.

Visit us at The Lazy Investor, our free investment newsletter.

Horizon Investment

Horizon — registered investment advisor seeks to provide investors at all stages the ability to build, preserve and enjoy wealth.

Visit us at Horizon Investment Services to get started in an investment program that's right for you.

Upside

Upside — discovers today's small and midcap stocks poised to be tomorrow's Blue Chip leaders.

Visit us at Upside, your guide to the best buys in small and midcap stocks.

Current Hotline

Friday, July 22, 2016

The housing market picked up in June

Read More from the Hotline

Stock Spotlight

LabCorp passes growth test

Wednesday, July 20, 2016

Laboratory Corp. of America ($137; LH), one of just two national laboratory operators, benefits from pricing power and the current environment of rising medical...

Read More from Stock Spotlight

Individual Stock Reports

ISRs make stock research easy!

Perhaps the most valuable two page reports available anywhere.

All the data you would normally have to plow through years of 10-K filings, earnings reports, and reams of market data to assemble — yours all in one concise report.

ISRs contain our proprietary Quadrix scores — find out how we rate all the stocks in the S&P 500.

Visit us at individualstockreports.com